Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating remibrutinib for efficacy and safety in secondary progressive multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Status: RECRUITING